SANDOZ-CALCITONIN NS LIQUID

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CALCITONIN (SALMON SYNTHETIC)

Saadav alates:

SANDOZ CANADA INCORPORATED

ATC kood:

H05BA01

INN (Rahvusvaheline Nimetus):

CALCITONIN (SALMON SYNTHETIC)

Annus:

200UNIT

Ravimvorm:

LIQUID

Koostis:

CALCITONIN (SALMON SYNTHETIC) 200UNIT

Manustamisviis:

NASAL

Ühikuid pakis:

200 U.I / SPRAY BOTTLE

Retsepti tüüp:

Prescription

Terapeutiline ala:

PARATHYROID AND ANTIPARATHYROID AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0111011001; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2013-10-01

Toote omadused

Sandoz Calcitonin NS
Page 1 of 35
PRODUCT MONOGRAPH
PR
SANDOZ CALCITONIN NS
Synthetic Calcitonin (Salmon)
Nasal Spray
200 IU/actuation
Bone Metabolism Regulator
Sandoz Canada Inc.
Date of Revision:
145 Jules-Léger
October 12, 2010
Boucherville, Quebec
J4B-7K8
Control number : 140901
Sandoz Calcitonin NS
Page 2 of 35
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................3
SUMMARY PRODUCT
INFORMATION.............................................................................3
INDICATIONS AND CLINICAL
USE...................................................................................3
CONTRAINDICATIONS........................................................................................................4
WARNINGS AND
PRECAUTIONS......................................................................................4
ADVERSE
REACTIONS........................................................................................................5
DRUG
INTERACTIONS........................................................................................................10
DOSAGE AND
ADMINISTRATION....................................................................................11
OVERDOSAGE
……………………………………………………………………….........12
ACTION AND CLINICAL
PHARMACOLOGY..................................................................12
STORAGE AND
STABILITY...............................................................................................15
SPECIAL HANDLING
INSTRUCTIONS............................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................15
PART II: SCIENTIFIC
INFORMATION..........................................................................16
PHARMACEUTICAL
INFORMATION...............................................................................16
CLINICAL
TRIALS....................................................